EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Editorial: Breaking barriers: new frontiers in immunotherapy for resistant cancers

Rahul Shivahare, Po-Lan Su, Swati Dubey, Annapurna Gupta

Frontiers in Oncology · 19.11.2026 · 16

DOI: 10.3389/fonc.2026.2052892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.11.2026. Verfasst von Rahul Shivahare und 3 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has transformed the therapeutic landscape of multiple malignancies, with immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 producing durable responses in subsets of patients. However, primary resistance and disease progression after an initial response remain major barriers to extending these benefits more broadly. Increasing evidence indicates that immunotherapy resistance is not a single biological state but rather a dynamic and heterogeneous process involving tumor-intrinsic alterations, impaired antigen presentation and interferon signaling, oncogenic and metabolic reprogramming, T-cell dysfunction, and remodeling of the tumor microenvironment (TME) (1)(2)(3)(4). Recent studies have further emphasized the contribution of myeloid populations, stromal and vascular components, immune-exclusion programs, and additional inhibitory checkpoints to resistance to immune checkpoint blockade (3,5). At the same time, the limitations of individual biomarkers such as PD-L1 have stimulated efforts to develop multidimensional and longitudinal approaches to predicting therapeutic response (6). This Research Topic, "Breaking Barriers: New Frontiers in Immunotherapy for Resistant Cancers", brings together nine articles encompassing mechanistic reviews, original research, and clinically informative case reports. Collectively, these contributions illustrate the complexity of therapeutic resistance while highlighting emerging opportunities to overcome it through TME remodeling, personalized antigen targeting, adoptive cellular therapy, immune rechallenge, targeted-immunotherapy combinations, and molecularly informed treatment selection.Jiang et al. reported a 57-year-old patient with recurrent anaplastic thyroid carcinoma with a squamous-cell component and concurrent thyroid abscess. Following surgery, radiotherapy, and poorly tolerated chemotherapy, the disease recurred within 8 months. Anlotinib monotherapy produced only minimal tumor reduction, whereas subsequent combination therapy with anlotinib and the PD-1 inhibitor tislelizumab resulted in marked regression of the recurrent neck mass and cervical lymphadenopathy after 12 cycles, achieving a partial response. Notably, benefit was observed despite PD-1 negativity. This case highlights the potential synergistic activity of antiangiogenic targeted therapy and immune-checkpoint blockade in aggressive, treatment- Collectively, these approaches aim to improve ICD-induced antitumor immunity by simultaneously modifying the tumor microenvironment, supporting combination strategies that may enhance the efficacy and durability of cancer immunotherapy.Wang et al. retrospectively evaluated immune-checkpoint inhibitor rechallenge in 13 patients with advanced NSCLC who had developed acquired immune resistance after an initial response to PD-1/PD-L1 blockade. Rechallenge achieved a disease-control rate of 61.5%, although no objective responses were observed, and the median progression-free survival was 2.9 months. Poor ECOG performance status was associated with significantly shorter progression-free survival, while toxicity during rechallenge was generally manageable. These findings suggest that selected patients with acquired immune resistance may derive modest clinical benefit from ICI rechallenge, while highlighting the need for prospective studies and biomarkers to identify those most likely to respond.Tang et al. retrospectively evaluated neoadjuvant pembrolizumab combined with paclitaxel and cisplatin in 83 patients with locally advanced oropharyngeal or hypopharyngeal squamous-cell carcinoma. Compared with chemotherapy alone, pembrolizumab-based chemoimmunotherapy achieved a higher objective response rate (91.3% vs. 55.2%), increased transoral surgery feasibility (91.3% vs. 34.5%), and reduced tracheostomy requirements. In hypopharyngeal cancer, the objective response rate reached 100%, while the primary-tumor pathological complete-response rate was 57.9%, exceeding that observed with cetuximab-based therapy. Although survival differences were not yet significant, these findings support neoadjuvant chemoimmunotherapy as a promising organ-preserving strategy in locally advanced disease. Mo et al. reported a 55-year-old patient with EGFR exon 19-mutant lung adenocarcinoma and baseline malignant pleural effusion who developed resistance to sequential gefitinib and almonertinib. Repeat genomic profiling of pleural fluid revealed persistent EGFR sensitizing alterations together with multiple newly acquired mutations, but no T790M, MET amplification, or small-cell transformation; PD-L1 expression was high (TPS 40%). Ivonescimab monotherapy achieved disease control for nearly 5 months, followed by continued benefit with ivonescimab plus pemetrexed. This case highlights the value of repeated molecular profiling at progression and suggests that dual PD-1/VEGF-A blockade may offer a treatment option for molecularly complex EGFR-TKI-resistant disease.

Zitieren

APA

Shivahare, R., Su, P., Dubey, S., & Gupta, A. (2026). Editorial: Breaking barriers: new frontiers in immunotherapy for resistant cancers. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2052892

Vancouver

Shivahare R, Su P, Dubey S, Gupta A. Editorial: Breaking barriers: new frontiers in immunotherapy for resistant cancers. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2052892

BibTeX
@article{Shivahare2026,
  author = {Shivahare, Rahul and Su, Po-Lan and Dubey, Swati and Gupta, Annapurna},
  title = {Editorial: Breaking barriers: new frontiers in immunotherapy for resistant cancers},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.2052892}
}
Kostenlos starten →